Ibruxen Capsule 140mg (Ibrutinib 140mg)
Ibrutinib is a small-molecule inhibitor of BTK. Ibrutinib forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. BTK’s role in signaling through the B-cell surface receptors results in activation of pathways necessary for B-cell trafficking, chemotaxis, and adhesion. Nonclinical studies show that ibrutinib inhibits malignant B-cell proliferation and survival in vivo as well as cell migration and substrate adhesion in vitro.
Description
Ibruxen 140 mg Ibrutinib is an anti-cancer medicine. It works by blocking an abnormal protein that signals cancer cells to multiply. Ibruxen Ibrutinib helps stop the spread of cancer cells.
FAQ about Ibruxen 140 mg Ibrutinib
Q: What are Ibruxen 140 mg Ibrutinib side effects?
Ibruxen has some side effects
- Difficulty having a bowel movement.
- heartburn or indigestion
- muscle stiffness or spasms
- small red or purple spots on the skin
- stomach discomfort, upset, or pain
- swelling or inflammation of the mouth
Q: What is the cost of ibruxen ibrutinib?
In the US ibrutinib costs $484 per capsule/tablet regardless of the strength 140mg. source here
In the UK the cost of a year’s course of ibrutinib treatment is £55,954.50 (excluding VAT) source here
But you can get this medicine at an affordable price from us. for order contact us
Q: What is the drug ibrutinib used for?
Ibrutinib is a type of targeted cancer drug. It is a treatment for mantle cell lymphoma. Chronic lymphocytic leukemia
Q: What cancers does ibrutinib treat?
A drug used alone or with other drugs to treat adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenstrom macroglobulinemia (a type of non-Hodgkin lymphoma), mantle cell lymphoma, or marginal zone lymphoma.
Q: How quickly does ibrutinib work?
Ibrutinib is a very effective CLL drug and provides evidence of rapid patient benefit concerning symptoms improving, lymph nodes decreasing, and blood counts improving. For some, a very good partial or clinical complete response can emerge clinically within 3-6 months
Dosage & Administration
MCL: 560 mg taken orally once daily (four 140 mg capsules once daily)
CLL and WM: 420 mg taken orally once daily (three 140 mg capsules once daily)
Capsules must be swallowed whole with water. Do not open, break, or chew them.
Use in Pregnancy & Lactation
Pregnancy Category D
Based on animal data, Ibrutinib can cause fetal harm when administered to a pregnant woman. A patient who uses this drug during pregnancy or becomes pregnant while taking it should be apprised of the potential hazard to the fetus.
There is no information available on whether Ibrutinib is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Ibrutinib, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Pediatric Use
Ibrutinib has not been proven to be safe and effective in children.
Geriatric Use
There were no significant differences in the safety or effectiveness of the drug between elderly and younger subjects. Cardiac adverse events (atrial fibrillation and hypertension), infections (pneumonia, urinary tract infection, and cellulitis), and gastrointestinal events (diarrhea and dehydration) occurred more frequently among elderly patients.
Reviews
There are no reviews yet.